Subscribe to RSS
DOI: 10.1055/s-0038-1625972
Erratum: Quebec Platelet Disorder: Update on Pathogenesis, Diagnosis, and Treatment
Address for correspondence
Publication History
Publication Date:
14 January 2019 (online)
The publisher has been informed that there were errors in [Table 1] in the above article in Seminars in Thrombosis and Hemostasis, Volume 37, Number 6, 2011 (DOI: 10.1055/s-0031-1291382).
Abbreviations: ADP, adenosine diphosphate; aPTT, activated partial thromboplastin time; PT (INR), prothrombin time (international normalized ratio); QPD, Quebec platelet disorder; uPA, urokinase plasminogen activator.
Note: The only correction in this table, as compared with the previous version, relates to plasma thrombopoietin levels. All other information is as per previously published. The entire table is provided here for completeness and ease of referral.
The plasma thrombopoietin (TPO) values and TPO assay reference interval that the authors were provided were incorrect. They apologize for not catching these errors before publication. Plasma TPO levels (determined with new samples and the same assay) are actually <31.3 pg/ml in QPD and most general population control samples.[1] A new version of [Table 1], with the correct information,[1] is included in this erratum. No other information in the authors' review requires correction.
#
No conflict of interest has been declared by the author(s).
-
References
- 1 Hayward CP, Tasneem S, Rivard GE. Thrombopoietin levels in Quebec platelet disorder: Implications for the mechanism of thrombocytopenia. Int J Lab Hematol 2018 Doi: 10.1111/ijlh.12781
Address for correspondence
-
References
- 1 Hayward CP, Tasneem S, Rivard GE. Thrombopoietin levels in Quebec platelet disorder: Implications for the mechanism of thrombocytopenia. Int J Lab Hematol 2018 Doi: 10.1111/ijlh.12781